Popular Articles

GlaxoSmithKline Pledges $97M Investment In AIDS Drugs For Africa, Allows South African Drugmaker To Produce Generic Second-Line Treatment
GlaxoSmithKline (GSK) on Tuesday announced plans to invest $97 million over 10 years "to improve research, development and access to AIDS drugs in Africa," Reuters reports. GSK also put forth "a new free voluntary licensing agreement for AIDS drug abacavir, or Ziagen with South African generic drugmaker Aspen Pharmacare." According to Reuters, Aspen will be able to "manufacture a cheaper generic version of the drug."
generic viagra online
Systems Biology Recommended As A Clinical Approach To Cancer
Four researchers at the Virginia Bioinformatics Institute (VBI) at Virginia Tech and their colleagues at the Wake Forest University School of Medicine are advocating the use of systems biology as an innovative clinical approach to cancer. This approach could result in the development of improved diagnostic tools and treatment options, as well as potential new drug targets to help combat the many potentially fatal types of the disease.
News of the day
New Cervical Cancer Campaign, UK
There will be a new drive to ensure GPs spot cervical cancer symptoms earlier in young women and refer patients correctly, Health Minister Ann Keen announced today.
Nutrition

Globe And Mail Examines RTS,S Malaria Vaccine Trials In Kenyan Town

The Globe and Mail examines GlaxoSmithKline"s RTS,S malaria vaccine trials in Kilifi, Kenya - one of the sites where the experimental vaccine is being tested. "The stories of the mothers of Kilifi open a window on the challenges faced by researchers as they build a trial that will include more than 16,000 babies from 11 sites spread across sub-Saharan Africa," the Globe and Mail reports. The first five babies taking part in the trial, which has also received funds from the Bill & Melinda Gates Foundation, were vaccinated in Tanzania in late May. Now researchers and medical professionals are "readying millions of dollars worth of new laboratory equipment, training field workers and canvassing mothers in rural villages in Burkina Faso, Gabon and Ghana in the west, Mozambique and Malawi in the south and Kenya and Tanzania in the north to sign up the final volunteers," according to the Globe and Mail. Patricia Njuguna, a pediatrician who is a "principle investigator on the crucial phase-three trials," first came to Kilifi as a medical officer. Last year, Njuguna and colleagues worked with "dozens of field workers and clinicians on a smaller trial of the same vaccine" that broke "new ground," and showed that "rates of malaria among babies and toddlers who received the vaccine were 53 percent lower than those of children who did not," the newspaper writes. However, spreading "enthusiasm" about the vaccine trials to "poor villages buried at the rough ends of old roads, where medical care is rare and deadly illnesses abundant, is no small feat," writes the Mail and Guardian. According to the article, suspicion and skepticism are some of the major obstacles in recruitment. But the newspaper reports that the "meticulous explanations and consent required to bring malaria trials to an international standard seems to be winning the trust of Kilifi"s people, if not always the understanding" (Alsop, Mail and Guardian, 6/16). This information was reprinted from globalhealth.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives and sign up for email delivery at globalhealth.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):